• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·SUDARSHAN.BO
Share

Sudarshan Pharma Industries Ltd. Stocks

₹ 41.82Last Updated 24.07.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

₹ 108.17M

₹ 41.82
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Sudarshan Pharma Industries Ltd. operates as a supplier of specialty chemicals, intermediates, and active pharmaceutical ingredients. The company strategically sources its products externally to cater to clients both within India and internationally. Additionally, the firm is active in contract manufacturing and provides outsourced generic pharmaceutical formulations and various medicines. These are supplied to a broad spectrum of clients, including healthcare institutions, governmental agencies, non-profit organizations, and hospitals. Established on July 23, 2008, Sudarshan Pharma maintains its corporate headquarters in Mumbai, India.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.07.2026 19:59

Sam Altman didn't believe in a four-hour workweek made possible by AI. Why?

27.07.2026 19:16

Freedom was the first on Wall Street to believe in Intrepid, a small-cap potash producer. Why?

27.07.2026 18:47

A lull in the war in the Middle East boosted U.S. stocks: The Dow rose more than 1%

27.07.2026 18:30

A 10-fold growth, Korea’s golden age, and a lesson from China: Highlights from an interview with the head of Nvidia

27.07.2026 18:02

A Magnet for Startups: Why Are Fintech Startups and Neobanks Flocking to Colombia?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026